1-20 of 27
Li Meng
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Ponatinib 2-Year Efficacy, Safety and Health-Related Quality of Life in Patients with Philadelphia Chromosome-Positive Leukemia: An Open-Label, Multicenter, Phase 2 Clinical Trial in China

Lu Yu, Huifang Wang, Xiaoli Liu, Bingcheng Liu, Xielan Zhao, Qun He, Qingshu Zeng, Zimin Sun, Ting Liu, Huanling Zhu, Zhuogang Liu, Xin Du, Jie Jin, Li Meng, Ming Hou, Suning Chen, Linhua Yang, Mingji Xian, Yoshitaka Kotobuki, Shuang Zhang, Qian Jiang
Journal: Blood
Blood (2024) 144 (Supplement 1): 6602.
https://doi.org/10.1182/blood-2024-208258
Published: 2024
Journal Articles

Variables Associated with Outcomes in Patients with Chronic Neutrophilic Leukemia with CSF3R T618I : A Multi-Centre Retrospective Study

Qian Jiang, Na Xu, Xiaoli Liu, Li Meng, Suning Chen, Jianyong Li, Linhua Yang, Chun-Yan Chen, Limei Chen, Jie Sun, Ling Pan, Minghui Duan, Hongmei Jing, Jinhai Ren, Fengru Lin, Xuemei Qin, Junqing Xu, Robert Peter Gale, Mingfeng Zhao, Zhilan Pan, Xianhua Yuan, Lijuan Cui, Zhijian Xiao, Li Weiming
Journal: Blood
Blood (2024) 144 (Supplement 1): 1793.
https://doi.org/10.1182/blood-2024-207591
Published: 2024
Journal Articles

Olverembatinib-Therapy in Patients with Accelerated-Phase Chronic Myeloid Leukaemia: A Multi-Centre Retrospective Study from China

Mengyao Yuan, Li Zhou, Xin Du, Jianyu Weng, Linhua Yang, Yanping Ma, Shasha Zhao, Zhenfang Liu, Qin Wen, Qingxian Bai, Xianqi Feng, Yanqiu Han, Aifang Li, Chunshui Liu, Qing Leng, Li Meng, Baohong Wang, Xuehong Ran, Xiaodong Wang, Haiguo Zhang, Yun Zeng, Yanli Zhang, Qian Jiang
Journal: Blood
Blood (2024) 144 (Supplement 1): 1767.
https://doi.org/10.1182/blood-2024-206453
Published: 2024
Journal Articles

Safety and Efficacy of Tgrx-678, a Potent BCR::ABL1 allosteric Inhibitor, in Patients with Tyrosine Kinase Inhibitor Resistant and/or Intolerant Chronic Myeloid Leukemia: Updated Results of Phase 1 Study Tgrx-678 -1001

Qian Jiang, Li Weiming, Yanli Zhang, Qiang Wang, Suning Chen, Bingcheng Liu, Zhuogang Liu, Jie Jin, Zhenfang Liu, Jianyu Weng, Xin Du, Xielan Zhao, Li Meng, Lie Lin, Wanlin Ye, Shujie Yan, Yihan Wang, Jingrong Cao
Journal: Blood
Blood (2024) 144 (Supplement 1): 477.
https://doi.org/10.1182/blood-2024-205300
Published: 2024
Journal Articles

Metabolic and Cell Cycle Proteins As Novel Targets of Selinexor Activity in Diffuse Large B Cell Lymphoma

Kyla L. Trkulja, Will Tong, Daisy V. Tran, Li Meng, Evelyn Teh, Susanne Penny, Devanand M. Pinto, Armand Keating, John Kuruvilla, Rob C. Laister
Journal: Blood
Blood (2024) 144 (Supplement 1): 4179.
https://doi.org/10.1182/blood-2024-208314
Published: 2024
Journal Articles

Olverembatinib 30 Mg Versus 40 Mg Every Other Day (QOD) in Patients with Tyrosine Kinase Inhibitor (TKI) Resistant or Intolerant Chronic-Phase Chronic Myeloid Leukemia (CML-CP): A Multi-Center Propensity Score-Matched Analysis

Xiaoshuai Zhang, Lu Yu, Li Zhou, Yanli Zhang, Huanling Zhu, Bingcheng Liu, Xin Du, Xiaodong Wang, Linhua Yang, Yanping Ma, Li Meng, Yanqing Zhang, Guohui Li, Lijie Yang, Baohong Wang, Xuehong Ran, Jian Huang, Qin Wen, Yan Wen, Yuxia Zhao, Yu Zhu, Yanqiu Han, Zhenfang Liu, Xin Du, Jianyu Weng, Qian Jiang
Journal: Blood
Blood (2024) 144 (Supplement 1): 4529.
https://doi.org/10.1182/blood-2024-203533
Published: 2024
Journal Articles

Olverembatinib-Based Therapy in Patients with Philadelphia Chromosome-Positive Acute Leukemia: A Multi-Centre Retrospective Study from China

Mei Bao, Jian Huang, Huiying Qiu, Suning Chen, Shengli Xue, Xiaofei Yang, Zhenfang Liu, Chunyan Chen, Linhua Yang, Yanping Ma, Li Meng, Yanli Zhang, Li Weiming, Qin Wen, Guohui Li, Lijie Yang, Yanqiu Han, Xiaodong Wang, Yan Wen, Congmeng Lin, Hai Yi, Xingli Zhao, Yanqing Zhang, Yang Song, Qian Jiang
Journal: Blood
Blood (2024) 144 (Supplement 1): 4528.
https://doi.org/10.1182/blood-2024-205232
Published: 2024
Journal Articles

A predictive model for therapy failure in patients with chronic myeloid leukemia receiving tyrosine kinase inhibitor therapy

Clinical Trials & Observations
Xiaoshuai Zhang, Bingcheng Liu, Jian Huang, Yanli Zhang, Na Xu, Robert Peter Gale, Weiming Li, Xiaoli Liu, Huanling Zhu, Ling Pan, Yunfan Yang, Hai Lin, Xin Du, Rong Liang, Chunyan Chen, Xiaodong Wang, Guohui Li, Zhuogang Liu, Yanqing Zhang, Zhenfang Liu, Jianda Hu, Chunshui Liu, Fei Li, Wei Yang, Li Meng, Yanqiu Han, Li’e Lin, Zhenyu Zhao, Chuanqing Tu, Caifeng Zheng, Yanliang Bai, Zeping Zhou, Suning Chen, Huiying Qiu, Lijie Yang, Xiuli Sun, Hui Sun, Li Zhou, Zelin Liu, Danyu Wang, Jianxin Guo, Liping Pang, Qingshu Zeng, Xiaohui Suo, Weihua Zhang, Yuanjun Zheng, Xiaojun Huang, Qian Jiang
Journal: Blood
Blood (2024) 144 (18): 1951–1961.
https://doi.org/10.1182/blood.2024024761
Published: 2024
Includes: Supplemental data
Journal Articles

Olverembatinib (HQP1351) Demonstrates Efficacy Vs. Best Available Therapy (BAT) in Patients (Pts) with Tyrosine Kinase Inhibitor (TKI)-Resistant Chronic Myeloid Leukemia Chronic-Phase (CML-CP) in a Registrational Randomized Phase 2 Study

Qian Jiang, Zongru Li, Gongli Zhang, Yu Hu, Weiming Li, Yongping Song, Junmin Li, Li Zhou, Bingcheng Liu, Xiaoli Liu, Na Xu, Suning Chen, Zhenfang Liu, Huanling Zhu, Jie Jin, He Huang, Sixuan Qian, Li Meng, Xin Du, Xielan Zhao, Sujun Gao, Yang Liang, Ming Hou, Wei Wang, Zi Chen, Qian Niu, Lichuang Men, Dajun Yang, Yifan Zhai, Xiaojun Huang
Journal: Blood
Blood (2023) 142 (Supplement 1): 869.
https://doi.org/10.1182/blood-2023-187740
Published: 2023
Journal Articles

Evaluating Effectiveness and Safety of Flumatinib for Chronic Phase Chronic Myeloid Leukemia in (CML-CP) without Optimal Response (Warning, Failure) to Imatinib or/and Dasatinib

Li Weiming, Yanli Zhang, Zhiwei Wu, Qin Wen, Qing Leng, Shuting Wu, Xiaodong Wang, Shiming Chen, Guolin Yuan, Sixuan Qian, Suning Chen, Daozi Jiang, Lianjun Diao, Zhenfang Xi, Hui Wu, Hui Sun, Lijie Yang, Hongjuan Wang, Xuefang Zhang, Yanli Xu, Xielan Zhao, Na Xu, Li Meng, Zunmin Zhu, Youfang Zhao, Meifang Su, Zhuangzhi Yang, Chuancai Liu, Danlei Han, Yu Hu
Journal: Blood
Blood (2023) 142 (Supplement 1): 3171.
https://doi.org/10.1182/blood-2023-179142
Published: 2023
Journal Articles

Safety and Efficacy of Flumatinib in Patients with Chronic Myeloid Leukemia Resistant or Intolerant to Imatinib

Yuntao Liu, Yunfan Yang, Hui Sun, Li Meng, Hai Lin, Chunyan Chen, Jianda Hu, Xuliang Shen, Minghui Duan, Yanli Zhang, Dilinazi Abulaiti, Jinghua Wang, Hongqian Zhu, Luoming Hua, Qing Leng, Chun Zhang, Lili Sun, Weiming Li, Huanling Zhu, Bingcheng Liu, Jianxiang Wang
Journal: Blood
Blood (2023) 142 (Supplement 1): 6367.
https://doi.org/10.1182/blood-2023-190780
Published: 2023
Journal Articles

Flumatinib Versus Nilotinib for Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia

Suning Chen, Yanli Zhang, Na Xu, Hui Sun, Li Weiming, Yunfan Yang, Zunmin Zhu, Minghui Duan, Sixuan Qian, Yu Zhu, Jianmin Luo, Xiaodong Wang, Wei Yang, Weiying Gu, Fei Li, Bingcheng Liu, Yunxiao Xu, Zhenfang Liu, Chunling Wang, Yirong Jiang, Li Meng, Qin Wen, Yanli Xu, Xingli Zou, Wei Wang, Yan Xue, Hao Xu, Kehong Bi, Fuling Zhou, Liangming Ma, Rong Fu, Guifang Ouyang, Kaiyang Ding, Depei Wu
Journal: Blood
Blood (2023) 142 (Supplement 1): 1797.
https://doi.org/10.1182/blood-2023-179073
Published: 2023
Journal Articles

Subjects with Chronic Myeloid Leukemia Identified As Intermediate- or High-Risk Subjects Using the Imatinib Therapy Failure (IMTF) Model Benefit from Initial Therapy with a Second-Generation Tyrosine Kinase Inhibitor

Xiaoshuai Zhang, Bingcheng Liu, Jian Huang, Gongli Zhang, Xiaoli Liu, Na Xu, Weiming Li, Xin Du, Jianyu Weng, Hai Lin, Rong Liang, Chunyan Chen, Huanling Zhu, Ling Pan, Yun-fan Yang, Xiaodong WANG, Guohui Li, Zhuogang Liu, Zhenfang Liu, Jianda Hu, Chunshui Liu, Li Fei, Wei Yang, Li Meng, Robert Peter Gale, Xiao Jun Huang, Qian Jiang
Journal: Blood
Blood (2022) 140 (Supplement 1): 3891–3894.
https://doi.org/10.1182/blood-2022-168812
Published: 2022
Journal Articles

Is the 2 nd Generation Tyrosine Kinase-Inhibitor a Better Initial Therapy Than Imatinib in Persons with Chronic Myeloid Leukemia Presenting in Accelerated Phase: A Multicenter Retrospective Study

Sen Yang, Xiaoshuai Zhang, Yanli Zhang, Xin Du, Jianyu Weng, Huanling Zhu, Ling Pan, Yun-fan Yang, Li Meng, Zhenfang Liu, Xiaoli Liu, Na Xu, Chunyan Chen, Xiaodong WANG, Rong Liang, Jian Huang, Guohui Li, Chunshui Liu, Hai Lin, Jianda Hu, Li Fei, Bingcheng Liu, Weiming Li, Zhuogang Liu, Wei Yang, Xiao Jun Huang, Qian Jiang
Journal: Blood
Blood (2022) 140 (Supplement 1): 815–817.
https://doi.org/10.1182/blood-2022-166855
Published: 2022
Journal Articles

Updated Results of Pivotal Phase 2 Trials of Olverembatinib (HQP1351) in Patients (Pts) with Tyrosine Kinase Inhibitor (TKI)-Resistant Chronic- and Accelerated-Phase Chronic Myeloid Leukemia (CML-CP and CML-AP) with T315I Mutation

Qian Jiang, Zongru Li, Yue Hou, Yu Hu, Weiming Li, Xiaoli Liu, Na Xu, Yanli Zhang, Yongping Song, Li Meng, Zhenya Hong, Bingcheng Liu, Yan Li, Suning Chen, Mengxing Xue, Huanling Zhu, He Li, Xin Du, Jin Lou, Xiaohan Zhang, Yang Liang, Yu-Jun Dai, Zi Chen, Qian Niu, Lichuang Men, Dajun Yang, Yifan Zhai, Xiao-Jun Huang
Journal: Blood
Blood (2022) 140 (Supplement 1): 203–204.
https://doi.org/10.1182/blood-2022-170698
Published: 2022
Journal Articles

Olverembatinib Based Therapy in Recurrent Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia with BCR/ABL Mutation

Qiuxia Lv, Qiuxia Yu, Yang Cao, Jue Wang, Yicheng Zhang, Gaoxiang Wang, Zhenya Hong, Li Meng
Journal: Blood
Blood (2022) 140 (Supplement 1): 11688–11689.
https://doi.org/10.1182/blood-2022-157416
Published: 2022
Journal Articles

Validation and Use of Predictive Scoring Systems for Molecular Responses in 5,203 Persons with Chronic Myeloid Leukemia

Xiaoshuai Zhang, Bingcheng Liu, Jian Huang, Gongli Zhang, Xiaoli Liu, Na Xu, Weiming Li, Xin Du, Jianyu Weng, Hai Lin, Rong Liang, Chunyan Chen, Huanling Zhu, Ling Pan, Yunfan Yang, Xiaodong WANG, Guohui Li, Zhuogang Liu, Zhenfang Liu, Jianda Hu, Chunshui Liu, Li Fei, Wei Yang, Li Meng, Robert Peter Gale, Xiao Jun Huang, Qian Jiang
Journal: Blood
Blood (2022) 140 (Supplement 1): 9620–9623.
https://doi.org/10.1182/blood-2022-166431
Published: 2022
Journal Articles

A Predictive Scoring System for Therapy Failure in Persons with Chronic Myeloid Leukemia Receiving Initial a Second-Generation Tyrosine Kinase Inhibitor Therapy

Xiaoshuai Zhang, Bingcheng Liu, Jian Huang, Gongli Zhang, Xiaoli Liu, Na Xu, Weiming Li, Xin Du, Jianyu Weng, Hai Lin, Rong Liang, Chunyan Chen, Huanling Zhu, Ling Pan, Yun-fan Yang, Xiaodong WANG, Guohui Li, Zhuogang Liu, Zhenfang Liu, Jianda Hu, Chunshui Liu, Li Fei, Wei Yang, Li Meng, Robert Peter Gale, Xiao Jun Huang, Qian Jiang
Journal: Blood
Blood (2022) 140 (Supplement 1): 9637–9639.
https://doi.org/10.1182/blood-2022-168703
Published: 2022
Journal Articles

The Safety and Efficacy of p CAR-19B, a Scfv Humanlized CD19-Directed CAR-T for Patients with Relapsed/Refactory (R/R) CD19+ B-ALL

Zhenya Hong, Zhi Yang, Xiaoxi Zhou, Gaoxiang Wang, Mi Zhou, Yingzi Zhang, Peiling Zhang, Jinjin Huang, Li Meng, Haitao Ruan, Min Xiao, Yunyan Li, Linling Wang, Meiling Wang, Wei Zhu, Qianzhen Zhang, Junjie Shen, Jianfeng Zhou, Cheng Qian, Liang Huang
Journal: Blood
Blood (2022) 140 (Supplement 1): 4625–4626.
https://doi.org/10.1182/blood-2022-162134
Published: 2022
Journal Articles

Efficacy and Safety of Generic Dasatinib As First-Line Treatment in Patients with Chronic Myeloid Leukemia in Chronic Phase: Final Analysis with 2-Year Follow-up

Jie Jin, Li Meng, Wenjuan Yu, Peng Liu, Xin Du, Jin Lou, Weiguang Wang
Journal: Blood
Blood (2021) 138 (Supplement 1): 3616.
https://doi.org/10.1182/blood-2021-150197
Published: 2021